Everolimus-eluting resorbable scaffold superior to angioplasty for CLTI due to infrapopliteal artery disease

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-10-30 14:00 GMT   |   Update On 2023-10-31 04:44 GMT

The results of the LIFE-BTK trial indicate that an everolimus-eluting resorbable scaffold is more effective than balloon angioplasty in reducing lower extremity limb events.In terms of the primary efficacy endpoint, the use of an everolimus-eluting resorbable scaffold is more effective than angioplasty among patients with chronic limb-threatening ischemia (CLTI ) due to infrapopliteal...

Login or Register to read the full article

The results of the LIFE-BTK trial indicate that an everolimus-eluting resorbable scaffold is more effective than balloon angioplasty in reducing lower extremity limb events.

In terms of the primary efficacy endpoint, the use of an everolimus-eluting resorbable scaffold is more effective than angioplasty among patients with chronic limb-threatening ischemia (CLTI ) due to infrapopliteal artery disease, says Varcoe et al. and colleagues in there recent study published in The New England Journal of Medicine.

Among patients with CLTI and infrapopliteal artery disease, angioplasty is tied to frequent reintervention and adverse limb outcomes from restenosis. There needs to be more data available regarding the effect of the use of drug-eluting resorbable scaffolds on these outcomes. This was further investigated in the present study.

This multi-centre, randomized, controlled trial had 261 patients with chronic limb-threatening ischemia (CLTI) and infrapopliteal artery disease (2:1 ratio). The patients received either an everolimus-eluting resorbable scaffold or an angioplasty.

Freedom from amputation above the ankle, occlusion of the target vessel, clinically driven revascularization of the target lesion, and binary restenosis of the target lesion at 1 year was the primary efficacy endpoint.

The primary safety endpoint was freedom from major adverse limb events at six months and perioperative death.

Key results from the study are:

  • No events occurred (primary efficacy end point) in 135/173 patients in the scaffold group and 48/88 patients in the angioplasty group.
  • Kaplan–Meier estimate was 74% vs 44%, and the absolute difference was 30 percentage points.
  • The primary safety endpoint was observed in 165 /170 patients (97%) and 90/90 patients (100%) in the scaffold and angioplasty groups, respectively. The absolute difference was −3 percentage points.
  • Serious adverse events (index procedure-related) occurred in 2% of the patients in the scaffold group and 3% in the angioplasty group.

In conclusion, considering the primary efficacy endpoint, using an everolimus-eluting resorbable scaffold is superior to angioplasty in patients with CLTI due to infrapopliteal artery disease. It could be a novel strategy for reducing lower extremity limb outcomes.

Abbott funded the study.

Reference:

Ramon L. Varcoe. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease.October 25, 2023. DOI: 10.1056/NEJMoa2305637

Tags:    
Article Source : The New England Journal of Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News